RxDoctor Payments Data

Kayla Ehrman, DO

Geriatric Medicine · Bettendorf, IANPI 1316357494

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $179,313 of the $201,687 with a category attached, or 88.9%. 19 manufacturers reported payments, led by CSL Plasma Inc. at 53.6% of the total. 2025 is the largest year on record at $51,533, 2.8 times the $18,125 reported in 2020.

$201,687in general payments, 2019–2025

Across 270 payments — averaging $746.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Plasma Inc.$108K
  • CSL Behring$71K
  • Lilly USA, LLC$21K
  • Eisai Inc.$671
  • Lundbeck LLC$98
  • Otsuka America Pharmaceutical, Inc.$97
  • plus $428 from 13 others

What the payments were for

  • Consulting fees$179,31389%
  • Speaking & faculty fees$17,7009%
  • Travel & lodging$2,3961%
  • Food & beverage$2,2781%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few geriatric medicine providers in Iowato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$90,948
Medicare patients
373
Services billed
729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban704$255,277
OzempicSemaglutide98$100,321
XareltoRivaroxaban181$61,373
JardianceEmpagliflozin132$50,509
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$42,201
Invega SustennaPaliperidone Palmitate13$31,105
RexultiBrexpiprazole26$29,093
LinzessLinaclotide45$26,111
TradjentaLinagliptin87$23,206
TrulicityDulaglutide22$22,384
MyrbetriqMirabegron50$21,373
Tresiba Flextouch U-100Insulin Degludec111$19,657
FarxigaDapagliflozin Propanediol38$16,638
Atorvastatin Calcium936$16,308
JanuviaSitagliptin Phosphate52$15,926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Restasis$39$32,68158 claims
Otsuka America Pharmaceutical, Inc.Rexulti$97$29,09326 claims
Lilly USA, LLCTrulicity$21,062$22,38422 claims
NovartisEntresto$67$9,49421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric medicine providers in Iowaon file to place this against a meaningful peer group, so we don't.

Other geriatric medicine in Bettendorf

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →